Introduction. Many countries have implemented cancer patient pathways (CPPs) for organ-specific cancers. However, due to high symptom diversity, it can be difficult for the General Practitioner (GP) to decide on the appropriate CPP. Objective. The aim of this study was to estimate the proportion of patients who were referred to a second CPP, were diagnosed with cancer or died within 6 months after receiving a negative result from clinical investigation through an initial CPP. Methods. We conducted a historical cohort study using routinely collected data with 6 months of follow-up. Data were collected from Danish registries. Results. We included 109 998 study subjects: 0.6% received a cancer diagnosis, 2.3% died and 6.1% were referred to a second CPP within 6 months. A total of 48.9% of the re-referrals after a first CPP in the gastrointestinal (GI) area were also referred to a second CPP in the GI area. Re-referral to a second CPP corresponded to a positive predictive value (PPV) of 4.4% to be diagnosed with cancer. Conclusion. A total of 6% of patients who received a negative result after investigation in an organspecific CPP were re-referred within 6 months to a new organ-specific CPP; many of these were in the same anatomical area as the first CPP. The PPV of 4.4% to be diagnosed with cancer indicates that some cancers may be missed in the diagnostic investigation through the first CPP. This calls for reconsideration of how CPPs may best support the primary cancer diagnosis.
Introduction
Urgent cancer referrals have been implemented in many western countries to ensure better access to timely cancer diagnosis and ultimately to improve survival rates (1) (2) (3) (4) . In Denmark, 33 organspecific cancer patient pathways (CPPs) have been introduced, and the General Practitioner (GP) can refer patients to further diagnostic testing on the basis of selected criteria, such as alarm symptoms, for specific types of cancer.
It can be a difficult task for the GP to identify the patients who might have cancer. Many alarm symptoms of cancer are highly prevalent among patients seen in general practice and yet have low positive predictive value (PPV) for cancer (5) (6) (7) . Furthermore, 40-50% of cancer patients present in general practice with vague non-specific symptoms such as fatigue, pain and weight loss (8, 9) . As non-specific symptoms can be caused by a number of different cancers, it can be challenging for the GP to select the most appropriate organ-specific CPP.
Although 88% of the Danish cancer cases are diagnosed through at least one CPP (10) , it is unknown to what extent patients undergo multiple CPPs before a final diagnosis of cancer is made. Multiple CPPs could lead to longer diagnostic intervals for the patients, with possible negative prognostic consequences (2) . Yet, to our knowledge, no previous study has looked into this.
The aim of this study was first to estimate the proportion of patients who were diagnosed with cancer, died or were re-referred for cancer investigation through a second CPP within 6 months after ending an initial CPP with a negative diagnosis. Second, we aimed to investigate potential overlaps between the CPPs referred to. Finally, we aimed to estimate the proportion of cancers detected through referral to a second CPP while considering the time frame and the site of the initial CPP.
Method
We conducted a historical cohort study using routinely collected data with 6-month follow-up of patients who had completed an initial CPP investigation with no verified cancer diagnosis.
Setting
The study took place in Denmark, which has ~5.6 million inhabitants and an annual cancer incidence rate of 326 per 100 000 (agestandardized world population). All Danish citizens have free access to health care through the publicly funded health care system, and around 98% of Danish citizens are listed with a GP, who acts as a gatekeeper to the rest of the health care system (except for emergencies and private otorhinolaryngologists and ophthalmologists, who can be accessed directly).
The Danish CPPs were introduced by national law in October 2007, and the CPPs were sequentially implemented throughout 2008 and 2009. The Danish CPP guidelines state specific criteria for urgent referral and describe well-defined diagnostic entities in the time until treatment, including limited time frames (1) . In 2015, ~127 000 citizens in Denmark were investigated for cancer through a CPP (10).
Population
Our study population consisted of all patients completing a first-time CPP with no verified cancer diagnosis between 1 January 2014 and 30 June 2015.
Patients were identified through the Danish National Patient Register (NPR) (11) with any code for a CPP (NPR code AFB***) registered in the study period and no CPP registered before 1 January 2014. All patients aged ≥18 years with at least one diagnostic course were assessed for eligibility (n = 166 381).
Patients were eligible if they ended the CPP either with no diagnosis of cancer (registered with NPR code AFB**X1) or on the patient's request (registered with NPR code AFB**X2). Patients, who ended a CPP by own request were included under the assumption that these patients did not finalize their diagnostic workup (10) . Thus, all patients registered to have started cancer treatment in the CPP (NPR code AFB**F* (n = 39 667)) or to have been offered cancer treatment (NPR codes of AFB**C* (n = 16 522)) were deemed ineligible.
In total, 110 192 patients fulfilled the eligibility criteria. We excluded 194 patients due to missing information on gender or age in the registers. Thus, we included 109 998 study subjects in the study.
Outcomes
The primary outcomes were defined as a second CPP, death or a subsequent cancer diagnosis within 6 months after initial CPP conclusion. These outcomes were included regardless of the order in which they occurred. A second CPP was defined as a CPP course registered with both a start date and an end date within 6 months after the end date of the first CPP.
A subsequent cancer diagnosis was defined as a cancer diagnosis registered in the Danish Cancer Register (DCR) (12) between 14 days and 6 months after the end date of the initial CPP, regardless of whether the cancer was diagnosed within the CPP framework or not.
Information on death was based on the vital status recorded in the Danish Civil Registration System (13) if this was registered in the period between the end date of the initial CPP and 6 months after this end date.
Other variables
Patients were described by gender, age, comorbidity, educational level, disposable income and marital status. Information on gender and age was retrieved from the Danish Civil Registration System. Based on registrations of diagnoses in the NPR 10 years before the start date of the first CPP, we computed the level of morbidity as measured by the Charlson Comorbidity Index (CCI) (14) . We grouped CCI scores into 'none' (no recorded disease), 'moderate' (index scores of 1 and 2) and 'high' (index scores of 3 or more). Information on education, household income and marital status was obtained from Statistics Denmark (15). Level of education was categorized Table 2 . First cancer patient pathway (CPP) undertaken by anatomical site, specific type of cancer suspected and type of conclusion among 109 998 patients who concluded an initial CPP with no verified cancer diagnosis from 1 January 2014 to 30 June 2015 
Statistical measures
First, differences in outcome frequencies across patient characteristics were summarized and compared between subgroups (e.g. men versus women) using Wilcoxon rank sum test, Pearson's chi-square test or Fischer's exact test, as appropriate. Second, CPPs were categorized according to the anatomical site of the cancer investigated in the CPP [i.e. the CPP for stomach cancer was categorized as gastrointestinal (GI) cancer], and differences in outcome frequencies across these anatomical groups of CPPs were summarized using frequencies and compared using Pearson's chi-square or Fischer's exact test, as appropriate.
Sensitivity analyses, excluding patients who were registered to have opted out on own request in the initial CPP, were undertaken to ensure that the inclusion of these patients did not alter the results.
Results
Of the included 109 998 patients, 55.7% were women, and 66.7% were aged 45-74 years. Most patients were married (58.9%), had no comorbidity (62.6%) and had a medium level of education (61.6%). All characteristics varied slightly between men and women ( Table 1) .
The highest proportions of CPPs by anatomical location were found for the GI system (35.9%), breast (14.7%) and lung (11.6%). The first CPP ended for 97.2% of the cases with no cancer diagnosis, whereas the remaining patients opted out (Table 2) .
In total, 693 (0.6%) of the patients received a new cancer diagnosis during follow-up (irrespective of the patient undergoing a second CPP). Among the patients who opted out on own request, 1.7% (men: 1.3%; women: 2.1%) received a cancer diagnosis ( Table 3 ). The patients who opted out on own request constituted 7.6% of the patients who got a cancer diagnosis (men: 6.6%; women: 8.5%). In total, 295 of the patients (42.6%) received the cancer diagnosis during the second CPP (Table 4) ; this resulted in a PPV of 4.4% (95% CI: 3.9-4.9) for detecting cancer when undergoing a second CPP and 7.4% (95% CI: 5.4-9.9) when undergoing a third CPP. The proportion of cancers detected within the time frame of the second CPP varied across the sites of the initial CPPs: from 3.8% (initial prostate CPP) to 7.2% (initial malignant melanoma CPP) ( Table 4) . In total, 2580 patients (2.3%) died during follow-up (men: 2.8%; women: 2.0%). Patients opting out of the first CPP constituted 25.3% of the patients who died during follow-up (Table 3 ).
In total, 6697 patients (6.1%) underwent one or more additional CPPs during follow-up (men: 6.2%; women: 5.2%). Of these patients, 8 .5% underwent a third CPP of whom 9.6% underwent a fourth CPP (Table 3) .
At the anatomical level, 2782 (41.5%) of the second CPPs were related to the GI area, 908 (13.6%) were related to the pulmonary area, 817 (12.2%) were related to the urinary system and 673 (10.0%) were related to the head and neck area (Table 4 ). In six out of twelve instances, the most frequent second CPP was located in the GI area (Table 4) . A total of 1386 (49.8%) of the 2782 individuals who completed a CPP related to the GI area were re-referred to a second CPP that was also related to the GI area (Table 4) . At the organ-specific level, 1891 (28.2%) of the second CPPs were related to the colorectal area, 908 (13.6%) were related to the lung area, 817 (12.2%) were related to the urinary area and 747 (11.1%) were related to the oesophagus (Table 4 ). The proportion of re-referrals to a second CPP ranged from 2.2% among patients who were initially investigated in a breast CPP to 18.7% among patients who were initially investigated in an oesophagus CPP (Table 4) . The most frequent second organ-specific CPP overall was the colorectal CPP (Table 4) , but the most frequent organ-specific second CPP varied across the sites of the initial CPP. Sensitivity analyses, leaving out cases who opted out from the initial CPP (n = 3, 125) did not alter the results (data not shown).
Discussion
In this study of almost 110 000 patients going through an organ-specific (initial) CPP without receiving a diagnosis of cancer, we found that 0.6% received a cancer diagnosis, 2.3% died and 6.1% were referred to a second CPP within 6 months of follow-up. The most frequent anatomical site of the second CPP was the GI system, and the colorectal area was the most frequent organ-specific site. Many of the second CPPs were in the same anatomical area as the first CPP. For example, nearly half of the re-referred cases with a first CPP in the GI area were re-referred to a CPP in the GI area.
Strengths and limitations
A major strength of this study was the use of population-based prospective collected data. This minimized the risk of selection bias and ensured a high degree of transferability of findings to real-life settings. Another strength was the use of the Danish national registries (17) to collect data as this minimized the risk of information bias. A limitation of the study was that patients were only eligible for inclusion if an end date was registered for the first CPP. Hence, we might have missed some cases due to a missing end date. We have no information on why some end dates should be missing, but these patients might have been more ill and at higher risk of dying.
Our requirement of both a start date and an end date for a CPP infers a risk of misclassifying the number of CPPs undertaken. This could have led us to miss patients terminated in an (initial) CPP with no diagnosis of cancer, which might have lowered the number of included cases.
Due to delay in registrations in the DCR, we may have missed some new cancer diagnoses. This could have led to an underestimation of the proportion of cases with a new cancer diagnosis during the follow-up period. Additionally, we may have missed some diagnoses because the date of diagnosis in the DCR is defined as the date of admission, which may be at an earlier point in time than the end date of the first CPP. The opposite might also be the case at the end of the follow-up period. However, such misclassification would not depend on the rejection of a diagnosis in a CPP and would thus be non-differential.
A second CPP referral was defined as a CPP course registered with both a start date and an end date within 6 months after the end date of the first CPP. This may have led us to miss some second CPPs, which could have led to an underestimation of the number of second CPPs within 6 months.
The relatively high proportions of the outcomes may partly be attributable to the age distribution of the cases, as the risk of dying and of getting cancer increases with age. Yet, our findings regarding the proportions of outcomes occurring during followup are still valid. However, due to the competing risk between the outcomes, we cannot account for the risks in the individual patients.
Comparison with other findings
We have not been able to identify similar studies. Nevertheless, a Danish study showed that cancer patients had an increased number of contacts with a hospital 1-12 months before their diagnosis (18) . Although this study is based on data from before the CPP implementation in Denmark, it indicates, as our results, that some patients are prone to multiple diagnostic encounters before a cancer diagnosis.
The number of second CPPs within 6 months after an initial CPP, which was found in our study, seems counterintuitive as a rejection of a cancer diagnosis might be seen as reassurance that nothing serious is wrong (19) . In line with this, a British study found that an 'all clear' diagnosis after investigation of cancer alarm symptoms made the patient less inclined to consult a physician, which could delay help seeking for several months (20) . This contrasts our findings that more than 1 in 20 were referred to a new CPP, meaning that these patients did indeed consult a physician.
A Norwegian study found that, despite a 'cancer not likely' record by the GP, 0.6% of patients were subsequently diagnosed with cancer (21) . However, a cancer suspicion that proved to be correct was six times more likely to occur than an erroneous lack of suspicion (21) . They concluded that, besides symptoms and patient characteristics, the GP's gut feeling also influenced the suspicion of cancer. This may also be the case in our study as 6.1% of the patients were re-referred to a second CPP although no cancer diagnosis was given after the first CPP, and only 0.6% of all the patients received a cancer diagnosis within 6 months.
The risk of having cancer in Denmark in 2014 was ~800/100 000 person-years for people above 20 years of age (22) , implying that ~0.4% of the Danish population would be diagnosed with cancer within 6 months. This roughly corresponds to our finding that 0.6% receive a cancer diagnosis. These numbers might give the impression that it is not beneficial to re-refer the patient. However, our finding of a PPV of 4.4% to be diagnosed with cancer after re-referral to a CPP is similar to the PPVs reported for warning signs of cancer (5, 23) . Therefore, it seems feasible to re-refer the patient if cancer suspicion prevails, even after rejection of cancer after the initial investigation.
It has been argued that the referral criteria for urgent referrals are too specific because many cancer patients present with non-specific symptoms (9, 24) . Part of our findings support this as some patients are referred to multiple consecutive CPPs; many of these concern the same anatomical area. Furthermore, 42.6% of the patients who received a cancer diagnosis got the diagnosis within the time span of the second CPP; this suggests that these cancers were missed in the first CPP, which results in delayed treatment for cancer. This brings into question whether more non-specific referral criteria and/ or more broad CPPs, e.g. a gastrointestinal CPP, could be favourable.
Conclusion
After rejection of cancer in an organ-specific CPP, 6% of investigated patients are re-referred within 6 months to a new organ-specific CPP; many of these concern the same anatomical area as the first CPP. Particularly, patients who are initially referred to a gastrointestinal CPP seem prone to be re-referred. A re-referral to a second CPP has a PPV of 4.4% for finding cancer; this indicates that some cancers may be missed in the first CPP.
